Professor Nicole Soranzo

BSc, PhD, FMedSci, EMBO, MEA

Curriculum Vitae

•	T
(iirrent	Positions

	GUIZEN TOURON	
Jan 2023- Jan 2021- Oct 2015-	Associate Faculty, Wellcome Sanger Institute, Hinxton, UK Head of Genomics Research Centre - Population & Medical Genomics, Human Technopole, Milan, Italy Professor of Human Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK	
Previous Posi	tions	
1999-2002	Post-doctoral research fellow, University of Milan, Italy	
2002-2005	Post-doctoral research fellow, University College London, UK	
2005-2007	Senior Scientist, Pharmacogenomics Department, Johnson and Johnson Pharmaceutical	
2003-2007	Research and Development, Raritan, NJ, USA	
2007-2009	Senior Staff Scientist, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK	
2007-2009	Honorary Lecturer, King's College London School of Medicine, London, UK	
2008-2009		
2009-2011	Honorary Senior Lecturer, King's College London School of Medicine, London, UK	
2013-2015	Career Development Group Leader, Wellcome Trust Sanger Institute, Hinxton, UK Principal of Research, University of Cambridge, Cambridge, UK	
	Group Leader, Wellcome Trust Sanger Institute, Hinxton, UK	
2012-2017	1	
	2017-2022 Senior Group Leader, Wellcome Sanger Institute, Hinxton, UK	
Education and	d training	
1996-1999	PhD in Genetics and Biotechnology, University of Dundee, UK	
1989-1994	Bachelor of Science in Biological Sciences (110/110 cum laude), University of Milan, Italy	
	, and the second se	
Grants		
2012-2017	NIHR Cambridge Biomedical Research Centre, NIHR, (total £110,073,288), Co-	
20012 2001	applicant	
2012-2015	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator	
2013-2017	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Co-	
2013-2017	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant	
	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal	
2013-2017 2015-2018	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator	
2013-2017 2015-2018 2015-2018	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant	
2013-2017 2015-2018	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022	
2013-2017 2015-2018 2015-2018 2015-2020	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant	
2013-2017 2015-2018 2015-2018	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator	
2013-2017 2015-2018 2015-2018 2015-2020	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000),	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022 2019-2023	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000), Co-applicant	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022 2019-2023 2021-2022	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000), Co-applicant Chan Zuckerberg Foundation, £2,800,000, Principal Investigator	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022 2019-2023 2021-2022 2022-2027	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000), Co-applicant Chan Zuckerberg Foundation, £2,800,000, Principal Investigator Horizon Europe – NeuroCOV, European Commission, € 144,000.00, Co-applicant	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022 2019-2023 2021-2022	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000), Co-applicant Chan Zuckerberg Foundation, £2,800,000, Principal Investigator Horizon Europe – NeuroCOV, European Commission, € 144,000.00, Co-applicant Personalised Rna- Oriented MedIciNE in Italy Novel Therapeutics PROMINENT	
2013-2017 2015-2018 2015-2018 2015-2020 2019-2022 2019-2023 2021-2022 2022-2027	EpiGeneSys RISE 1 new investigator award, EU FP7, € 199,995, Principal Investigator ESPOD fellowship to Valentina Iotchkova, WT/ EMBL, £81,000 (total £162,000), Coapplicant Center for Therapeutic Target Validation, GSK/EMBL/WT, £131,336, Principal Investigator ESPOD fellowship to Na Cai, WT/ EMBL, £81,000 (total £162,000), Co-applicant NIHR Biomedical Research Unit in Donor Health and Genomics, NIHR, £217,022 (total £4,099,619), Co-applicant Target Validation Using Metabolomics, BioMarin Pharmaceuticals, £1,000,042, Principal Investigator Centre of Research Excellence, British Heart Foundation, £750,000 (total £5,996,000), Co-applicant Chan Zuckerberg Foundation, £2,800,000, Principal Investigator Horizon Europe – NeuroCOV, European Commission, € 144,000.00, Co-applicant	

2024 - 2026 Phenotypic Prediction from Population – Scale Single-Cell RNA-Seq, Chan Zuckerberg Initiative, \$110,059.00, Co-applicant

Awards and honours

2010	Paula und Richard von Hertwig-Preis for International Cooperation
	<u>U</u>
2012	MRC Suffrage Science Award
2014	Movers and Shakers in Biobusiness, BioBeats
2016	Top Italian Women Scientist
2018	Fellow of the Academy of Medical Sciences (FMedSci)
2019	Fellow of the European Molecular Biology Organisation (EMBO)
2020	Forbes Italia - Top 100 Italian Women 2020
2022	Member of the Academia Europaea (MAE)
2022	Best Female Scientists in the World 2022 Ranking Research.com

Positions of Trust and Institutional Roles (more recent)

2016- 2016- 2016- 2017- 2017- 2017-2019 2018-2021 2018-2022 2018-	Member of the Steering Committee, BHF Cambridge Centre of Excellence (CRE) Member of the Selection Committee, Investigator Awards, Academy of Finland Member of the Scientific Advisory Board, MRC Integrative Epidemiology Unit (IEU) Member of the Steering Committee, Cambridge Biomedical Research Centre (BRC) Member of the Expert Review Panel (Genetics and Genomics), Wellcome Trust Chair of the Equality in Science Committee, Wellcome Sanger Institute Chair of the Post-graduate Development Committee, Wellcome Sanger Institute Member of the Steering Committee, Cardiovascular Strategic Research Initiative (SRI)
2018	Member of the Management Committee, Human Technopole (HT)
2018	Member of the Board of Electors to the Professorship of Donor Health and Genomics (University of Cambridge)
2018	Member of the Review Panel, CIFAR Genetic Networks Program, Canada
2019-2022	Member of the Organising Committee, International Common Disease Alliance
2019-2022	Member of the Scientific Advisory Board, MRC WIMM Center of Computational Biology
2020	Member of the Recruitment panel, Director of Heart and Lung Institute, University of Cambridge
2020	Member of the Board of Electors to the Professorship of Molecular Endocrinology
2022	(University of Cambridge)
2022 2022	Member of the Evaluation Panel, CRG Bioinformatics and Genomics, Barcelona Member of the Evaluation Panel, Consolidator Grant, European Research Council
2022	Member of the Selection Committee for Group Leader in Computational Biology, The
	Francis Crick Institute
2022-	Member of the Scientific Advisory Board, Milieu Intérieur (MI) Consortium, Institut Pasteur, Paris
2022-	Member of the Executive Committee, International Common Disease Alliance (Global)
2022-	Member of the Scientific Advisory Board, Centre of Computational Biology, University of Lausanne
2023-	Member of the Scientific Advisory Board, GENCODE project 2023- Member of the Scientific Advisory Board, EMBL Human Ecosystems
2024-	Member of the International Evaluation Committee (IEC) for SciLifeLab
2025	Member of the Local Advisory Board for the conference CIBB2025 - Computational Intelligence Methods for Bioinformatics and Biostatistics

Publications

H-index = 137, 115,013 citations

87,584 citations H index = 126

Full list of publications: soranzo, nicole [AU] - Search Results - PubMed (nih.gov)

Garrison E, Guarracino A, Heumos S, Villani F, Bao Z, Tattini L, Hagmann J, Vorbrugg S, Marco-Sola S, Kubica Ashbrook DG, Thorell K, Rusholme-Pilcher RL, Liti G, Rudbeck E, Golicz AA, Nahnsen S, Yang Z, Mwaniki N Nobrega FL, Wu Y, Chen H, de Ligt J, Sudmant PH, Huang S, Weigel D, **Soranzo N**, Colonna V, Williams RW, Prins P. (2024) Building pangenome graphs. Nat Methods. 2024 Oct 21.

Bolognini D*., Halgren A., Lou R.N., Raveane A*., Rocha J.L., Guarracino A., **Soranzo N.,** Chin J., Garrison E., Sudmant P.H. (2024) Global diversity, recurrent evolution, and recent selection on amylase structural haplotypes it humans. Nature 634, 617–625

Kundu K., Tardaguila M., Mann A.L., Watt S., Ponstingl H., Vasquez L., Von Schiller D., Morrell N.W., Stegle O., Pastinen T., Sawcer S.J., Anderson C.A., Walter K., **Soranzo N**. (2022) Genetic associations at regulatory phenotypes improve fine-mapping of causal variants for 12 immune-mediated diseases. Nat Genet. 54(3):251-262

Cai N., [26 authors], and **Soranzo N**. (2021) Mitochondrial DNA variants modulate N-formylmethionine, proteostasis and risk of late-onset human diseases. Nat Med. 27(9):1564-1575.

Watt S., [25 authors] and **Soranzo N.** (2021) Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease. Nat Commun. 16;12(1):2298.

Vuckovic D., [110 authors] and **Soranzo, N**. (2020) The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell. 3;182(5):1214-1231.e11.

Iotchkova, V., Ritchie, G.R.S, Geihs, M., Morganella, S., Min, J.L., Walter, K., Timpson, N.J.; UK10K Consortium, Dunham, I., Birney, E., **Soranzo, N**. (2019) GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals. Nat Genet. Feb;51(2):343-353.

Tardaguila, M., **Soranzo, N.** (2019) Resolving variant-to-function relationships in hematopoiesis. Nat Genet. 51(4):581-583.

Ecker, S., [40 authors], **Soranzo, N*** and Paul, D*. (2017) Genome-wide analysis of differential transcriptional an epigenetic variability across human immune cell types. Gen Biol 26;18(1):18.

Iotchova, V., [66 authors], and **Soranzo, N.** (2016) Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps. Nat Genet. 48:1303-1312.

Astle, W.J., [45 authors], and **Soranzo, N**. (2016) The allelic landscape of human blood cell trait variation and link to common complex disease. Cell 167;5;1415-1429.e19

Chen, L., [80 authors], and **Soranzo, N**. (2016) Genetic drivers of epigenetic and transcriptional variation in hum immune cells. Cell 167;5;1398-1414.e24

Vasquez, L. J., Mann, A. L., Chen, L. and **Soranzo, N**. (2016). From GWAS to function: lessons from blood cells ISBT Science Series, 11: 211–219.

UK10K Consortium, [29 authors], and **Soranzo, N**. (2015). The UK10K project identifies rare variants in health and disease. Nature 526, 82-90.

Huang, J., [17 authors], and **Soranzo, N.** (2015). Improved imputation of low-frequency and rare variants using t UK10K haplotype reference panel. Nat Commun 6, 8111.

Chen, L., [67 authors, **Soranzo**, **N.**: 63], and Rendon, A. (2014). Transcriptional diversity during lineage commitment of human blood progenitors. Science 345, 1251033.

Timpson, N.J., [35 authors], and **Soranzo, N**. (2014). A rare variant in APOC3 is associated with plasma triglyceri and VLDL levels in Europeans. Nat Commun 5, 4871.

Shin, S.Y., [36 authors], and **Soranzo**, **N**. (2014). An atlas of genetic influences on human blood metabolites. Nat Genet 46, 543-550.

Shin, S.Y., [21 authors], and **Soranzo, N.** (2014). Interrogating causal pathways linking genetic variants, small molecule metabolites, and circulating lipids. Genome Med 6, 25.

Menni, C., [22 authors, **Soranzo**, **N**.: 21], and Spector, T.D. (2013). Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62, 4270-4276.

Paul, D.S., [11 authors, **Soranzo**, **N**.: 9], and Deloukas, P. (2013). Maps of open chromatin highlight cell typerestricted patterns of regulatory sequence variation at hematological trait loci. Genome Res 23, 1130-1141.

van der Harst, P., [195 authors, **Soranzo, N**.: 194], and Chambers, J.C. (2012). Seventy-five genetic loci influencing the human red blood cell. Nature 492, 369-375.

Soranzo, N. (2011). Genetic determinants of variability in glycated hemoglobin (HbA(1c)) in humans: review of recent progress and prospects for use in diabetes care. Curr Diab Rep 11, 562-569.

Gieger, C., [163 authors], and **Soranzo, N**. (2011). New gene functions in megakaryopoiesis and platelet formatic Nature 480, 201-208.

Suhre, K., [33 authors, **Soranzo**, **N**.: 32], and Gieger, C. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54-60.

Paul, D.S., [18 authors, **Soranzo**, **N.**: 16], and Deloukas, P. (2011). Maps of open chromatin guide the functional follow-up of genome-wide association signals: application to hematological traits. PLoS Genet 7, e1002139.

Soranzo, N., [177 authors], and Meigs, J.B. (2010). Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. Diabetes 59, 3229-3239.

International HapMap Consortium, [89 authors, **Soranzo**, **N**.: 47], and McEwen, J.E. (2010). Integrating commo and rare genetic variation in diverse human populations. Nature 467, 52-58.

Dupuis, J., [308 authors, **Soranzo**, **N**.: 5], and Barroso, I. (2010). New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42, 105-116.

Soranzo, N., [80 authors], and Gieger, C. (2009). A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 41, 1182-1190.

Ganesh, S.K., [62 authors, **Soranzo, N.:** 4], and Lin, J.P. (2009). Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 41, 1191-1198.

Soranzo, N., [29 authors], and Ouwehand, W.H. (2009). A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 113, 3831-3837.

Prokopenko, I., [108 authors, **Soranzo, N.:** 5], and Abecasis, G.R. (2009). Variants in MTNR1B influence fasting glucose levels. Nat Genet 41, 77-81.